June 3 (Reuters) - Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA PRESENTS CLINICAL VALIDATION OF THE IL4 RECEPTOR AS A BIOMARKER FOR MDNA55 IN RECURRENT GLIOBLASTOMA
* MEDICENNA THERAPEUTICS CORP - 75% OF IL4R(+VE) PATIENTS ACHIEVE DISEASE CONTROL FOLLOWING ONE TREATMENT WITH MDNA55
* MEDICENNA THERAPEUTICS CORP - ENROLMENT INTO PHASE 2B MDNA55-05 TRIAL HAS BEEN COMPLETED.